Clinical Trials Logo

Chronic Rhinitis clinical trials

View clinical trials related to Chronic Rhinitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06370468 Recruiting - Chronic Rhinitis Clinical Trials

The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis

Start date: April 27, 2024
Phase:
Study type: Observational

Chronic rhinitis affects 10-40% of China's population, or over 300 million people, and can lead to respiratory and psychological issues. Despite treatment progress, 30% of patients have poor outcomes, likely due to the disease's complexity and a lack of new treatment targets. The incidence is rising, but there's a lack of nationwide studies on its variations. This study addresses this through a multicentric survey to create a national database on chronic rhinitis, including epidemiological, clinical, and biological data. The goal is to understand chronic rhinitis's causes and risks, improve treatments, and develop preventive strategies. The study will survey 30,000 patients across China, using questionnaires and nasal exams, and preserve biological samples in a biobank for detailed analysis. This will lay the groundwork for understanding the disease's mechanisms, developing new diagnostics, and tailoring prevention and treatment approaches for different forms of chronic rhinitis.

NCT ID: NCT06128200 Recruiting - Chronic Rhinitis Clinical Trials

NEUROMARK Randomized Controlled Trial

Start date: October 10, 2023
Phase: N/A
Study type: Interventional

The NEUROMARK RCT Study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial.

NCT ID: NCT05937308 Recruiting - Chronic Rhinitis Clinical Trials

NEUROMARK Registry Study

Start date: June 12, 2023
Phase: N/A
Study type: Interventional

The NEUROMARK Registry Study is a prospective, multicenter, single-arm, post-market, interventional registry study to collect real-world evidence of the NEUROMARK System in subjects with chronic rhinitis.

NCT ID: NCT05648565 Recruiting - Chronic Rhinitis Clinical Trials

Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis

Start date: January 10, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effectiveness of radiofrequency ablation (RFA) of the posterior nasal nerve (PNN) in chronic rhinitis (CR) patients by comparing patient reflective total nasal symptom score (rTNSS) and nasal obstruction symptom evaluation (NOSE) , peak nasal inspiratory flow (PNIF) , and levels of Type 2 cytokines pre- and post-procedure.

NCT ID: NCT05626621 Recruiting - Chronic Rhinitis Clinical Trials

Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis

Start date: November 23, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to determine the best combination of drugs and drug delivery routes to treat surgically naive chronic rhinitis patients. The main question it aims to answer is: Do high volume, high pressure delivery mechanisms in nasal irrigation improve the efficacy of azelastine combined with nasal steroid mometasone as compared to the standard low pressure, low volume delivery mechanisms in nasal sprays? Subjects will complete six months of one of three medication regimens: 1. Saline irrigation followed by azelastine spray and mometasone spray 2. Mometasone saline irrigation 3. Azelastine saline irrigation combined with mometasone saline irrigation.

NCT ID: NCT01546662 Recruiting - Chronic Rhinitis Clinical Trials

A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.

EB-RH-02-11
Start date: October 2011
Phase: N/A
Study type: Interventional

The study will be conducted in two phases. First phase will be 16 weeks study to assess the safety, efficacy & to determine the most appropriate dose. Will consist of following visits. Phase II (Extended Follow-up): At the end of Day 112, an interim analysis will be conducted to assess the sustained efficacy of the investigational product and accordingly the study will enter into phase II.